Your shopping cart is empty!
WHAT IS BORTEZOMIB?
Bortezomib is a targeted therapy. Bortezomib is classified as a proteasome inhibitor. Bortezomib interferes with the growth of some cancer cells and keeps them from spreading in your body. Bortezomib is sometimes given after other cancer medications have been tried without successful treatment.
Bortezomib is used to treat multiple myeloma and also for the treatment of mantle cell lymphoma who have received at least one prior therapy. Bortezomib targets and inhibits the proteasome enzyme complex within the cell. Proteasome is part of the cellular machinery and has many functions within the cell, such as it helps to control the level of many of the proteins that help to regulate cell division and cell survival. By interfering with it's function this can lead to apoptosis (cell suicide).
POSSIBLE SIDE EFFECTS:
Bortezomib may cause a serious viral infection of the brain that can lead to disability or death. Call your doctor right away if you have any change in your mental state, decreased vision, or problems with speech or walking. These symptoms may start gradually and get worse quickly.
Also call your doctor at once if you have:
Common side effects may include:
numbness, tingling, or burning pain in your hands or feet; loss of appetite, nausea, vomiting; diarrhea, constipation, bloating; fever, chills, cold or flu symptoms; pale skin, easy bruising or bleeding; rash; or feeling tired.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
Prior to reconstitution, store intact vials at 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). Once reconstituted, the manufacturer recommends use within 8 hours of reconstitution.